CAR-macrophage: Breaking new ground in cellular immunotherapy
Frontiers in Cell and Developmental Biology · 03.10.2024 · 12
DOI: 10.3389/fcell.2024.1464218 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 03.10.2024. Verfasst von Ting Huang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan, China. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Chimeric Antigen Receptor (CAR) technology has revolutionized cellular immunotherapy, particularly with the success of CAR-T cells in treating hematologic malignancies. However, CAR-T cells have the limited efficacy of against solid tumors. To address these limitations, CAR-macrophages (CAR-Ms) leverage the innate properties of macrophages with the specificity and potency of CAR technology, offering a novel and promising approach to cancer immunotherapy. Preclinical studies have shown that CAR-Ms can effectively target and destroy tumor cells, even within challenging microenvironments, by exhibiting direct cytotoxicity and enhancing the recruitment and activation of other immune cells. Additionally, the favorable safety profile of macrophages and their persistence within solid tumors position CAR-Ms as potentially safer and more durable therapeutic options compared to CAR-T cells. This review explores recent advancements in CAR-Ms technology, including engineering strategies to optimize their anti-tumor efficacy and preclinical evidence supporting their use. We also discuss the challenges and future directions in developing CAR-Ms therapies, emphasizing their potential to revolutionize cellular immunotherapy. By harnessing the unique properties of macrophages, CAR-Ms offer a groundbreaking approach to overcoming the current limitations of CAR-T cell therapies, paving the way for more effective and sustainable cancer treatments.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan, China.
- School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, China.
- Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
- University of Chinese Academy of Sciences, Beijing, China.
Zitieren
APA
Huang, T., Bei, C., Hu, Z., & Li, Y. (2024). CAR-macrophage: Breaking new ground in cellular immunotherapy. Frontiers in Cell and Developmental Biology, 12. https://doi.org/10.3389/fcell.2024.1464218
Vancouver
Huang T, Bei C, Hu Z, Li Y. CAR-macrophage: Breaking new ground in cellular immunotherapy. Frontiers in Cell and Developmental Biology. 2024;12. doi:10.3389/fcell.2024.1464218
BibTeX
@article{Huang2024,
author = {Huang, Ting and Bei, Chenqi and Hu, Zhenhua and Li, Yuanyuan},
title = {CAR-macrophage: Breaking new ground in cellular immunotherapy},
journal = {Frontiers in Cell and Developmental Biology},
year = {2024},
volume = {12},
doi = {10.3389/fcell.2024.1464218}
}
EUVIMED